A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

← catalyst calendar

NCT06119581 · readout ≤ 467 d

Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.

Phase

Phase 3

Status

Recruiting

Study type

Interventional

Design

Randomized · Double · Treatment

Enrollment

1,264estimated

Sites

419

Countries

Australia, Austria, Belgium +26

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2023-12-21

actual

When the study began enrolling

Primary completion

Nov 2027

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Jan 2031

estimated

The whole study's end, after follow-up

First posted

2023-11-07

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-07-20

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Carcinoma, Non-Small-Cell Lung
Neoplasm Metastasis

Interventions

Drug: LY3537982 — also filed as Olomorasib
Drug: Pembrolizumab
Drug: Placebo
Drug: Cisplatin
Drug: Carboplatin
Drug: Pemetrexed

Primary outcomes

what the primary-completion date above is the date OF

Dose Optimization and Safety Lead-In Part B: Number of Participants with a Treatment Emergent Adverse Event(s) (TEAE)

measured Randomization to first documented progression of disease or death from any cause. (Estimated as approximately 1 year)

Part A and Part B: Progression-Free Survival (PFS)

measured Randomization to first documented progression of disease or death from any cause. (Estimated as approximately 1 year)

Publications

PMID 41940628 — linked by the registry

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed